Green Cross Holdings Corporation (KRX:005250)
South Korea · Delayed Price · Currency is KRW 13,660
+10 (0.07%)
Last updated: Apr 9, 2026, 2:26 PM KST
Green Cross Holdings Revenue
In the year 2025, Green Cross Holdings had annual revenue of 2.45T KRW with 11.19% growth. Green Cross Holdings had revenue of 619.49B in the quarter ending December 31, 2025, with 9.62% growth.
Revenue
2.45T
Revenue Growth
+11.19%
P/S Ratio
0.25
Revenue / Employee
17.02B
Employees
144
Market Cap
619.73B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.45T | 246.62B | 11.19% |
| Dec 31, 2024 | 2.20T | 146.92B | 7.14% |
| Dec 31, 2023 | 2.06T | -21.62B | -1.04% |
| Dec 31, 2022 | 2.08T | 239.00B | 12.99% |
| Dec 31, 2021 | 1.84T | 121.23B | 7.05% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Medy-Tox | 247.29B |
| GC Cell | 165.52B |
| MEDIPOST | 73.66B |
| Onconic Therapeutics | 53.39B |
| Pharmicell | 23.94B |
| SillaJen | 9.23B |
| Anterogen.Co.,Ltd. | 7.54B |
| GI Innovation | 5.84B |
Green Cross Holdings News
- 5 months ago - MedGenome Makes a Majority Investment in Leading Gujarat-Based Diagnostics Chain Green Cross to Expand Genomics Offerings Across India - Business Upturn